Evidence map›Paper›PMID 29954358›Full record

ArticleBMC cancer2018

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.

Yan Wang, Xi Cheng, Yue-Hong Cui, Jun Hou, Yuan Ji, Yi-Hong Sun, Zhen-Bin Shen, Feng-Lin Liu, Tian-Shu Liu

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yan WangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xi ChengDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yue-Hong CuiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jun HouDepartment of Pathology, Fudan University, Zhongshan Hospital, Shanghai, China.
Yuan JiDepartment of Pathology, Fudan University, Zhongshan Hospital, Shanghai, China.
Yi-Hong SunDepartment of General Surgery, Fudan University, Zhongshan Hospital, Shanghai, China.
Zhen-Bin ShenDepartment of General Surgery, Fudan University, Zhongshan Hospital, Shanghai, China.
Feng-Lin LiuDepartment of General Surgery, Fudan University, Zhongshan Hospital, Shanghai, China.
Tian-Shu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.tianshu@zs-hospital.sh.cn.
Sun Yat-sen University · CNFudan University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CN

Funding

STCSM (Shanghai Science and Technology Committee) 15411961900
6 · The paper itself

Abstract

backgroundThe aim of this study was to compare the efficacies of the XELOX and DOS regimens as preoperative chemotherapy in patients with locally advanced gastric cancer.

methodsAll cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively. Propensity score matching (PSM) was carried out to reduce selection bias based on age, gender, location, Lauren type, carcinoembryonic antigen level, clinical tumor stage, and clinical node stage.

resultsFrom January 2010 to December 2016, 248 patients were matched; 159 of them received the XELOX regimen and 89 the DOS regimen. The response rates in the XELOX and DOS groups were 34.5 and 38.1%, respectively (P = 0.823). After four cycles of chemotherapy, 111 patients (69.8%) in the XELOX group and 65 patients (73.0%) in the DOS group underwent radical surgery (P = 0.485). The median progression-free survival (33.0 months vs. 18.7 months, P = 0.0356) and the median overall survival (43.8 months vs. 29.1 months, P = 0.0003) were longer for patients who received the DOS regimen than for those who received the XELOX regimen. The occurrence of grade 3 to 4 toxicity was similar in the two groups.

conclusionsFor locally advanced gastric cancer patients, the DOS regimen showed more benefit than the XELOX regimen as preoperative chemotherapy, without any added toxicity effects.

Indexed as

Propensity ScoreAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemotherapy, AdjuvantDeoxycytidineDocetaxelDrug CombinationsFemaleFluorouracilHumansMaleMiddle AgedOxaliplatinCapecitabineDeoxycytidineDocetaxelDrug CombinationsFluorouracilOxaliplatinOxaloacetatesOxonic AcidS 1 (combination)TegafurCurative resection rateLocally advanced gastric cancerPreoperative chemotherapyPropensity score matching analysis

Identifiers

PMID29954358
PMCPMC6027771
OpenAlexW2809988289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.